Klotho Neurosciences (NASDAQ:KLTO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Klotho Neurosciences (NASDAQ:KLTO) to a sell rating in a research note released on Saturday morning.

Klotho Neurosciences Stock Performance

Klotho Neurosciences stock opened at $1.33 on Friday. The stock has a market cap of $43.21 million, a P/E ratio of -3.69 and a beta of 11.08. Klotho Neurosciences has a fifty-two week low of $0.11 and a fifty-two week high of $3.91. The firm’s fifty day moving average price is $0.67 and its 200-day moving average price is $0.45.

Klotho Neurosciences (NASDAQ:KLTO) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Klotho Neurosciences stock. Geode Capital Management LLC increased its stake in Klotho Neurosciences, Inc. (NASDAQ:KLTO) by 122.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 140,606 shares of the company’s stock after acquiring an additional 77,372 shares during the period. Geode Capital Management LLC owned about 0.52% of Klotho Neurosciences worth $68,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 20.07% of the company’s stock.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors.